Who’s Going to World ADC London 2027

Mar 8–11, 2027 London, UK ~700 attendees Website

75 organizations and 43 speakers at World ADC London 2027, a ~700-person, mostly industry meeting of European antibody-drug conjugate developers. As of Oct 8, 2026.

Format
Track
Top represented
Showing 1–17 of 75 organizations
OrganizationWorld ADC London 2027 Attendance
AstraZeneca
Cambridge, UK
Large pharma
Global pharmaceutical company whose ADCs include trastuzumab deruxtecan and datopotamab deruxtecan, co-developed with Daiichi Sankyo.
Talk
A Justified Limit for the Identification Threshold of Organic Impurities in Drug-Linker Intermediates Used to Produce Antibody-Drug Conjugates
Process & Analytical Development
Manufacturing & supply chain
Talk
Aseptic Manufacturing of Antibody-Drug Conjugates – From Process Development to Validation
Process & Analytical Development
Manufacturing & supply chain
Talk
Wed Mar 10
3:30pm
A Scalable Lysine Bioconjugation Platform: Reducing Development Burden as Clinical Demand Scales
Plenary
Process & analytical developmentManufacturing & supply chain
Also
Presenting at the meeting, beyond the sessions above
Iksuda Therapeutics
Newcastle upon Tyne, UK
Biotech
UK ADC developer with clinical programs and new payload classes, including a protein-alkylating payload.
Panel
Tue Mar 9
9:30am
CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies
Plenary · with Araris Biotech, Oxford BioTherapeutics, Boehringer Ingelheim
Clinical development
Panel
Tue Mar 9
5:00pm
Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation
Plenary · with Queen's University Belfast, University of Michigan, Callio Therapeutics
ADC discoveryClinical development
Talk
Novel ADC Designs Drive Improved Clinical Outcomes
Clinical Lessons
ADC discovery
Workshop
Thu Mar 11
1:00pm
Leveraging Clinical Outcomes & Performance to Inform the Development of Novel ADC Design
Post-conference workshop for Clinical Lessons · with Oxford BioTherapeutics
ADC discovery
Johnson & Johnson
New Brunswick, NJ
Large pharma
Healthcare company that develops and markets medicines, including cancer therapies, through its Innovative Medicine business.
Talk
ADC Regulatory CMC 101: Introducing Core Principles, Guidance & Challenges Facing ADC Drug CMC & Submissions
Pre-conference: 3rd Regulatory CMC Day
Also
Presenting at the meeting, beyond the sessions above
Pierre Fabre
Castres, France
Large pharma
French pharmaceutical and dermo-cosmetics group developing oncology medicines, including antibody-drug conjugates.
Workshop
Thu Mar 11
1:00pm
Manufacturing Bispecifics, Dual Payloads & Novel Formats (DACs, AOD, POCs) at Scale
Post-conference workshop for Process & Analytical Development
Manufacturing & supply chain
Also
Presenting at the meeting, beyond the sessions above
Roche
Basel, Switzerland
Large pharma
Pharmaceutical and diagnostics company developing medicines in oncology, immunology, neuroscience and other areas.
Workshop
Thu Mar 11
1:00pm
Designing the Next Generation of ADCs: Exploring Novel Constructs & Future Combination Strategies
Post-conference workshop for Discovery
Clinical development
VAR2 Pharmaceuticals
Copenhagen, Denmark
Biotech
Clinical-stage Danish biotech, spun out of the University of Copenhagen, developing therapies that target cancer-specific glycosaminoglycans.
Talk
From Target to Clinic – Development & Manufacturing of the First in Class VARTUMAB ADC
Manufacturing & Supply Chain
ADC discovery
Also
Presenting at the meeting, beyond the sessions above
Academic & healthcare
Public research university in Ann Arbor, Michigan.
Talk
Antibody Design for Effective ADCs: The Multiple Impacts of Fc Engineering
Pre-conference: 5th Novel Conjugates Day
Panel
Tue Mar 9
5:00pm
Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation
Plenary · with Queen's University Belfast, Callio Therapeutics, Iksuda Therapeutics
ADC discoveryClinical development
Workshop
Thu Mar 11
9:00am
Accelerating ADC Model Simulation with the Power of Artificial Intelligence & Machine Learning
Post-conference workshop for Pre-Clinical & Translation
Biotech
Oncology biotech discovering new cancer targets and developing antibody and ADC therapies, including the CD205-directed ADC OBT076.
Panel
Tue Mar 9
9:30am
CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies
Plenary · with Iksuda Therapeutics, Araris Biotech, Boehringer Ingelheim
Clinical development
Workshop
Thu Mar 11
1:00pm
Leveraging Clinical Outcomes & Performance to Inform the Development of Novel ADC Design
Post-conference workshop for Clinical Lessons · with Iksuda Therapeutics
ADC discovery
Academic & healthcare
Public research university in Belfast, Northern Ireland.
Workshop
Introduction to ADCs Day
Pre-conference: Introduction to ADCs Day
Panel
Tue Mar 9
5:00pm
Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation
Plenary · with University of Michigan, Callio Therapeutics, Iksuda Therapeutics
ADC discoveryClinical development
Amgen
Thousand Oaks, CA
Large pharma
Global biotechnology company with marketed medicines in oncology, inflammation and cardiovascular disease, and research in protein therapeutics.
Talk
Wed Mar 10
8:30am
Precision Delivery of Therapeutics with Antibodies Through Biology, Chemistry & AI
Plenary
ADC discovery
Biotech
Swiss biotech developing antibody-drug conjugates, including multi-payload conjugates, with a linker that attaches payloads to unmodified antibodies.
Panel
Tue Mar 9
9:30am
CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies
Plenary · with Iksuda Therapeutics, Oxford BioTherapeutics, Boehringer Ingelheim
Clinical development
Consulting & other services
Biopharmaceutical consultancy advising on drug discovery, preclinical and clinical development, and in-licensing of early-stage assets.
Talk
Opportunities for Improving the Translational Safety of ADCs From NHPs to Humans
Pre-conference: 4th Toxicity Day
Clinical development
Boehringer Ingelheim
Ingelheim, Germany
Large pharma
Family-owned German pharmaceutical company with human and animal health medicines and an oncology pipeline.
Panel
Tue Mar 9
9:30am
CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies
Plenary · with Iksuda Therapeutics, Araris Biotech, Oxford BioTherapeutics
Clinical development
Biotech
Clinical-stage biotech developing dual-payload ADCs, led by a HER2-targeted program, to counter tumor resistance.
Panel
Tue Mar 9
5:00pm
Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation
Plenary · with Queen's University Belfast, University of Michigan, Iksuda Therapeutics
ADC discoveryClinical development
Academic & healthcare
Cancer research center in Lyon run jointly by Inserm, CNRS, the University of Lyon and the Centre Léon Bérard.
Workshop
Thu Mar 11
1:00pm
Selecting & Validating Models for ADC Efficacy & Safety
Post-conference workshop for Pre-Clinical & Translational
Biotech
Biotech developing antibody-drug conjugates against a new class of targets it calls TAPAs.
Talk
TAPAs: A New Class of ADC Targets From Discovery to the Clinic
Discovery
Clinical development
Innovent Biologics
Suzhou, China
Large pharma
Chinese biopharmaceutical company with marketed antibody medicines and a pipeline that includes dual-payload ADCs.
Talk
Tue Mar 9
6:00pm
Over the Horizon: the Dual Payload Innovation
Plenary
ADC discovery

Explore the full World ADC London 2027 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in London. Leave your work email and we’ll be in touch.

Privacy

Download the full World ADC London 2027 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from companies at World ADC London 2027

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

When and where is World ADC London 2027?

17th World ADC London runs March 8–11, 2027, at Novotel London West in London, UK.

Where is the World ADC London 2027 program?

This guide lists every organization on the World ADC London 2027 program with its sessions; the full program is on the official website.

How do I register for World ADC London 2027?

Fees and registration are on the organizer's registration page.

What conference is this?

World ADC London is a European antibody–drug conjugate meeting, held for the 17th time March 8–11, 2027 in London. It brings together ADC discovery, preclinical and translational, clinical, process and analytical, and manufacturing teams from pharma and biotech with the CDMOs, CROs and suppliers that serve them: five tracks over two main days, a pre-conference seminar day and a post-conference workshop day.

What is in this guide?

Every organization we can place at World ADC London 2027 so far: the 43 speakers on the public speaker faculty rolled up to their companies and institutions (27 sessions named on the preliminary agenda, and 17 speakers whose sessions are not named yet), and the 40 partners from the public partner list with their tier, 15 of them Exhibition Partners — 75 organizations in one list. Speakers appear as job titles, never by name. The organizers publish no attendee list and no booth numbers.

How are organizations typed?

By the role an organization plays in ADC development: drug developers (large pharma and biotech), then the companies around them — CDMOs and CROs, instrument and equipment makers, reagent, material and model-system suppliers, software and data companies, and consultancies and other services — and academic, government and non-profit bodies. The track filters come from the track, seminar or workshop a session sits in.

How current is it?

Pulled from the public speaker faculty, the preliminary day-by-day agenda and the partner list on October 8, 2026, five months before the meeting. Most track sessions are not named yet: the organizers fill the agenda in the months before the meeting, and this guide will be refreshed as it does.

Browse World ADC London 2027 by

Organizations with their own page

45 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by World ADC or its organizers. Submit a correction